 KT-621: Compelling Clinical Profile
 KT-621 Phase 1 Healthy Volunteer Data Suggests Potential for Dupilumab-like Activity in a Pill

                               Robust STAT6 Degradation in Blood and                                                                         Reductions in Multiple Disease-Relevant
                                Skin Following Low Daily Oral Doses                                                                                    Type 2 Biomarkers
                        100                                                                                                                Serum TARC1 with                                                   Serum Eotaxin-32 with
                                                                                                Blood                                    14-Day KT-621 Dosing                                                 14-Day KT-621 Dosing
                                                                                                Skin
                                                                                                                                         Placebo n=18         50 mg QD n=8                                        Placebo n=18             50 mg QD n=8




STAT6 % Change from
                                                                                                                                         1.5 mg QD n=9        100 mg QD n=9                                       1.5 mg QD n=9            100 mg QD n=8
                        50                                                                                                               12.5 mg QD n=7       200 mg QD n=9                                       12.5 mg QD n=7           200 mg QD n=9
                                                                                                                                         25 mg QD n=8                                                             25 mg QD n=8




                                                                                                                                                                              Eotaxin-3 % Change from
                                                                                                                                                                                                        20
                                                                                                                               20




                                                                                                          TARC % Change from
                         0                                                                                                                                                                               0




 Baseline Mean (SE(±)
                                                                                                                                0
                                                                                                                                                                                                        -20




                                                                                                                                                                                  Baseline Median
                                                                                                            Baseline Median
                        -50                                                                                                    -20                                                                      -40


                                                                                                                                                                                                        -60
                                                                                                                               -40
                    -100
                              Placebo   1.5mg QD    12.5mg QD   25mg QD   50mg QD   100mg QD   200mg QD                                                                                                 -80
                                                                                                                                     1        4           7   14      28                                      1        4               7   14      28
            Blood N            18          9            7           9       9          9          9                                            ON TREATMENT                                                             ON TREATMENT


                Skin N         17          7            7           8       9          9          9
                                                                                                                                                  Time (Day)3                                                           Time (Day) 3

     Favorable safety profile: well-tolerated across all dose levels with safety profile
     undifferentiated from placebo

                                               visit Kymera’s website                                                                                                                                                                                      22
